Related Experiment Video
Updated: Aug 10, 2026
Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
Targeting signal transduction for disease therapy
1Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel. LEVITZKI@vms.huji.ac.il
Abstract:
With the advance in the molecular understanding of disease processes, it has been appreciated that many diseases result from the malfunctions of signaling pathways. This recognition has led to intensive research and the development of therapies based on the interception of cellular signaling in diseased cells. In the past two years, success has been achieved using a blocker of the farnesylation of Ras as a tumor inhibitor, a JAK-2 blocker as an efficient inhibitor of recurrent pre-B cell acute lymphoblastic leukemia, and a platelet-derived growth factor receptor kinase as a blocker of restenosis.
Insights
Targeting cellular signaling pathways has emerged as a promising therapeutic strategy. Recent successes include inhibitors for Ras farnesylation, JAK-2, and platelet-derived growth factor receptor kinase in treating various diseases.
Area of Science:
- Molecular biology
- Cellular signaling
- Therapeutic development
Background:
- Many diseases stem from malfunctioning cellular signaling pathways.
- Understanding molecular disease mechanisms drives therapeutic innovation.
- Targeting specific signaling pathways is a key research area.
Purpose of the Study:
- To highlight recent advancements in therapies targeting cellular signaling.
- To showcase the success of specific pathway inhibitors in disease treatment.
- To underscore the importance of molecular understanding in developing new treatments.
Main Methods:
- Review of recent therapeutic successes in targeting cellular signaling.
- Identification of key molecular targets and their inhibitors.
- Analysis of clinical outcomes for specific pathway-interception therapies.
Main Results:
- Successful inhibition of Ras farnesylation demonstrates tumor inhibition.
- JAK-2 blockers show efficacy in treating pre-B cell acute lymphoblastic leukemia.
- Platelet-derived growth factor receptor kinase inhibitors effectively block restenosis.
Conclusions:
- Targeting cellular signaling pathways offers effective therapeutic strategies for various diseases.
- Molecular insights into disease mechanisms are crucial for developing targeted therapies.
- Recent advancements validate pathway interception as a powerful approach in medicine.
